Carriage of Staphylococcus aureus among Injection Drug Users: Lower Prevalence in an Injection Heroin Maintenance Program Than in an Oral Methadone Program

Infection Control and Hospital Epidemiology

Volumn 25, Issue 2, 2004, Pages 133-137

  Bassetti, Stefano ^a   Wolfisberg, Lea ^a   Jaussi, Barbara ^a   Frei, Reno ^a   Kuntze, Marcus F ^b   Battegay, Manuel ^a   Widmer, Andreas F ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DIAMORPHINE; METHADONE;

ADULT; BACTERIUM CARRIER; CONTROLLED STUDY; FEMALE; HUMAN; INTRAVENOUS DRUG ABUSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PREVALENCE; REVIEW; RISK FACTOR; STAPHYLOCOCCUS AUREUS;

ADMINISTRATION, ORAL; ADULT; CARRIER STATE; FEMALE; HEROIN; HUMANS; INJECTIONS, INTRAVENOUS; MALE; METHADONE; OPIOID-RELATED DISORDERS; PREVALENCE; STAPHYLOCOCCUS AUREUS; SUBSTANCE ABUSE, INTRAVENOUS; SWITZERLAND;

EID: 1342332685     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/502364     Document Type: Review

References (22)

1. Cherubin CE, Sapira JD. The medical complications of drug addiction and the medical assessment of intravenous drug users: 25 years later. Ann Intern Med 1993;119:1017-1028.
2. Palepu A, Tyndall MW, Leon H, et al. Hospital utilization and costs in a cohort of injection drug users. CMAJ 2001;165:415-420.
3. Bassetti S, Hoffmann M, Bucher HC, Fluckiger U, Battegay M. Infections requiring hospitalization of injection drug users who participated in an injection opiate maintenance program. Clin Infect Dis 2002;34:711-713.
4. Saravolatz LD, Markowitz N, Arking L, Pohlod D, Fisher E. Methicillin-resistant Staphylococcus aureus: epidemiologic observations during a community-acquired outbreak. Ann Intern Med 1982;96:11-16.
5. Fleisch F, Zbinden R, Vanoli C, Ruef C. Epidemic spread of a single clone of methicillin-resistant Staphylococcus aureus among injection drug users in Zurich, Switzerland. Clin Infect Dis 2001;32:581-586.
6. Kluytmans J, van Belkum A, Verbrugh H. Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms and associated risks. Clin Microbiol Rev 1997;10:505-520.
7. von Eiff C, Becker K, Machka K, Stammer H, Peters G. Nasal carriage as a source of Staphylococcus aureus bacteremia. N Engl J Med 2001;344:11-16.
8. Peacock S, de Silva I, Lowy FD. What determines nasal carriage of Staphylococcus aureus? Trends Microbiol 2001;9:605-610.
9. Tuazon CU, Sheagren JN. Increased rate of carriage of Staphylococcus aureus among narcotic addicts. J Infect Dis 1974:129:725-727.
10. Kirmani N, Tuazon CU, Alling D. Carriage rate of Staphylococcus aureus among patients receiving allergy injections. Annals of Allergy 1980;45:235-237.
11. Rehm J, Gschwend P, Steffen T, Gutzwiller F, Dobler-Mikola A, Uchtenhagen A. Feasibility, safety, and efficacy of injectable heroin prescription for refractory opioid addicts: a follow-up study. Lancet 2001;358:1417-1420.
12. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing: Eleventh Informational Supplement. Wayne, PA: National Committee for Clinical Laboratory Standards; 2001. Document M100-S11.
13. Bassetti S, Dunagan DP, D'Agostino RB, Sherertz RJ. Nasal carriage of Staphylococcus aureus among patients receiving allergen-injection immunotherapy: associated factors and quantitative nasal cultures. Infect Control Hosp Epidemiol 2001;22:741-745.
14. Holbrook KA, Klein RS, Hartel D, et al. Staphylococcus aureus nasal colonization in HIV-seropositive and HIV-seronegative drug users. J Acquir Immune Defic Syndr 1997;16:301-306.
15. Shuter J, Hatcher VB, Lowy FD. Staphylococcus aureus binding to human nasal mucin. Infect Immun 1996;64:310-318.
16. Bibel DJ, Aly R, Shinefield HR, Maibach HI, Strauss WG. Importance of the keratinized epithelial cell in bacterial adherence. J Invest Dermatol 1982;79:250-253.
17. Lowy FD, Miller M. New methods to investigate infectious disease transmission and pathogenesis: Staphylococcus aureus disease in drug users. Lancet Infect Dis 2002;2:605-612.
18. Perneger TV, Giner F, del Rio M, Mino A. Randomised trial of heroin maintenance programme for addicts who fail in conventional drug treatments. BMJ 1998;317:13-18.
19. Steffen T, Blattler R, Gutzwiller F, Zwahlen M. HIV and hepatitis virus infections among injecting drug users in a medically controlled heroin prescription programme. Eur J Public Health 2001;11:425-430.
20. Naef MR, Bucher HC, Erb P, Gyr N, Bassetti S, Battegay M. Reduced infections with HIV and hepatitis A during a Swiss intravenous opiate maintenance program. J Acquir Immune Defic Syndr 1999;21:349-351.
21. Conrad C, Steffen T, Gutzwiller F. Die Entwicklung von Hauterkrankungen bei intravenös Drogenabhängigen in der heroingestützten Behandlung. Schweiz Rundsch Med Prax 2000;89:1899-1906.
22. Blanc DS, Pittet D, Ruef C, et al. Epidemiology of methicillin-resistant Staphylococcus aureus: results of a nation-wide survey in Switzerland. Swiss Med Wkly 2002;132:223-229.